STOK — Stoke Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.94bn
- $1.66bn
- $184.42m
Annual cashflow statement for Stoke Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -85.8 | -101 | -105 | -89 | -6.88 |
| Depreciation | |||||
| Non-Cash Items | 17.9 | 24.6 | 27.2 | 28.1 | 34.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.046 | 43 | -6.03 | -28.1 | 16.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -66.9 | -31.9 | -81.1 | -86.9 | 45.6 |
| Capital Expenditures | -1.2 | -3.96 | -1.62 | -0.203 | -0.67 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -75.2 | -41.9 | 108 | -107 | -186 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -76.4 | -45.9 | 106 | -107 | -187 |
| Financing Cash Flow Items | -0.002 | 45.3 | 52.1 | 8.96 | 87.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 1.28 | 46.4 | 53 | 131 | 97.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -142 | -31.3 | 77.9 | -63.2 | -43.8 |